Diagnosis and Management of Cholangiocarcinomas: A Comprehensive Review

Hepato-Gastroenterology

Volumn 51, Issue 55, 2004, Pages 43-50

  Yalcin, Suayib ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Biliary tract cancer; Carcinogenesis; Cholangio carcinoma; Diagnosis and treatment

Indexed keywords

ALKYLATING AGENT; ANABOLIC AGENT; ANTHRACYCLINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; ISONIAZID; METHOTREXATE; METHYLDOPA; MITOMYCIN C; NITROSOUREA; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; THORIUM DIOXIDE; UFT;

BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CAROLI DISEASE; CHEMICAL ENVIRONMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMMON BILE DUCT CYST; DEVELOPMENTAL BIOLOGY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; FASCIOLIASIS; HUMAN; META ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FLUOROURACIL; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 10744226403     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Nakeeb A, Pitt HA, Sohn TA, et al: Cholangiocarcinoma: a spectrum of intrahepatic, perihilar and distal tumors. Ann Surg 1996; 224:463-475.
2. Klatskin G: Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: An unusual tumor with distinctive clinical and pathological features. Am J Med 1965; 38:241-256.
3. Bismuth H, Nakache R, Diamond T: Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31-38.
4. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. Ca Cancer J Clin 1998; 48:6-29.
5. Lowenfels AB, Maisonneuve P: Pancreatico-biliary malignancy: Prevalence and risk factors. Annals Oncol 1999; 10(Suppl 4):1-3.
6. Chapman RW: Risk factors for biliary tract carcinogenesis. Annals Oncol 1999; 4(Suppl 4):308-311.
7. Kornfeld D, Ekbom A, Ihre T: Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterology 1997; 32:1042-1045.
8. Holzinger F, Z'graggen K, Buchler MW: Mechanisms of biliary carcinogenesis: A pathogenetic multi-stage cascade towards cholangiocarcinoma. Annals Oncol 1999; 10(Suppl 4):122-126.
9. Haswell-Elkins MR, Satarug S, Tsuda M, et al: Liver fluke infection and cholangiocarcinoma: Model of endogeneous nitirc oxide and extragastric nitrosation in human carcinogenesis. Mutation Res 1994; 305:241-252.
10. Ekbom A, Hsieh CC, Yuen J, et al: Gall stones and bile duct cancer. Gastroenterology 1994; 107:1205-1206.
11. Kaczynski J, Hansson G, Wallerstedt S: Incidence etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma. A study of 51 cases from a low-endemicity area. Acta Oncol 1998; 37:77-83.
12. Ohashi K, Tstsumi M, Nakajima Y, et al: Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer 1996; 74:930-935.
13. Pan G, Vickers SM, Pickens A, et al: Apoptosis and tumorigenesis in human cholangiocarcinoma cells: Involvement of Fas/APO-1 (CD95) and calmudilin. Am J Pathol 1999; 155:193-203.
14. Tannapfel A, Engeland K, Weinans L, et al: Expression of p73 a novel protein related to the p53 tumour suppressor/53 and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 1999; 80:1069-1074.
15. Terada T, Nakanuma Y, Sirica A: Immunohistochemical demonstration of MET overexpression in human intrahepetic cholangiocarcinoma and in hepatolithiasis. Human Pathol 1998; 29:175-180.
16. Ozaki S, Harada K, Sanzen T, Watanabe K, Tsui W, Nakanuma Y: In situ nucleic axid detection of telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion. Hepatology 1999; 30:914-919.
17. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, Kanno S, Saito E: Assesment of the expression o fp53, MIB-1 (Ki-67 Antigen) and Argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 1998; 82:86-95.
18. Takao S, Uchikura K, Yonezawa S, et al: Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to liver and poor prognosis. Cancer 1999; 86:1966-1975.
19. Smits NJ, Reeders JWAJ: Imaging and staging of biliopancreatic malignancy: role of ultrasound. Ann Oncol 1999; 10(Suppl 4):20-24.
20. Thorsen MK, Quiroz F, Lawson TL, et al: Primary biliary carcinoma: CT evaluation. Radiology 1984; 152:479-483.
21. Low RN: Magnetic resonance imaging of the abdomen: applications in the oncology patient. Oncology 2000; 14(Suppl 6):5-14.
22. Nakajima T, Kondo Y, Miyazak M, Okui K: A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Human Pathol 1988; 19:1228-1234.
23. Sasaki A, Kawano K, Aramaki M, Nakashima K, Yoshida T, Kitano S: Immunohistochemical expression of cytokeratins in intrahepatic cholangiocarcinoma and metastatic adenocarcinoma of the liver. J Surg Oncol 1999; 70:103-198.
24. Madariaga JR, Iwatsuki S, Todo S, et al: Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Annals Surg 1998; 227:70-79.
25. Goldstein RM, Stone M, Tillery WW, Senzer N, Levy M, Husberg BS, Gonwa T, Klintmalm G: Is liver transplantation indicated for cholangiocarcinoma. Am J Surg 1993; 166:768-772.
26. Hejna M, Pruckmayer MK, Raderer M: The role of Chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998; 34:977-986.
27. Pitt HA, Nakeeb A, Abrams RA, et al: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Annals of Surg 1995; 221:788-798.
28. Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI: The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiotion Oncol Biol Phys 1996; 34:767-774.
29. Bowling TE, Galbraith SM, hatfield AR, et al: A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996; 39:852-855.
30. Karani J, Fletcher M, Brinkley D, Dawson JL, Williams R, Nunnerley H: Internal biliary drainage and local radiotherapy with iridium-192 wire in the treatment of hilar cholangiocarcinoma. Clin Radiol 1985; 36:603-606.
31. Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, Liau CT: Weekly 24 h infusion of high-dose 5-flourouracil and leucovorin in patients with biliary tract carcinomas. Anti-Cancer Drugs 1998; 9:393-397.
32. Taal BG, Audisio RA, Bleiberg H, Blijham GH, et al: Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Annals Oncol 1993; 4:607-609.
33. Harvey JH, Smith FP, Schein PS: 5-flourouracil, Mitomycin, and Doxorubucin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2:1245-1248.
34. Takada T, Kato H, Matsushiro T, Nimura T, Nagakawa T, Nakayama T: Comparison of 5-flourouracil, doxorubicin and mitomycin-C with 5-flourouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51:396-400.
35. Kajanti M, Pyrhonen S: Epirubicine-sequential metotrexate-5-flourouracil- leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17:223-226.
36. Ducreux M, Rougier P, Fandi A, Clavero-Fabry MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-flourouracil continous infusion with cisplatin. Annals Oncol 1998; 9:653-656.
37. Ellis PA, Norman A, Hill A, O'Brien MER, Nicolson M, Hickish T, Cunningham D: Epirubucin, cisplatin and infusional 5-flourouracil (5-FU) in hepatobiliary tumours. Eur J Cancer 1995; 31A:1594-1598.
38. Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, Benner S: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs 1999; 17:97-101.
39. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ: Phase II Study of Paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 13:2306-2310.
40. Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM, Burris HA: Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 1999; 22:78-81.
41. Glimelius B, Hoffman K, Sjoden PO, Sellstrom H, Enander LK: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals Oncol 1996; 7:593-600.